A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

1. 18 to 55 years old, inclusive, at day of signing Informed Consent Form (ICF)

2. General good health, without significant uncontrolled medical illness, based on medical history, physical examination, vital signs, and clinical laboratories (CBC, chemistry, and urinalysis) as determined by the investigator in consultation with the Research Monitor and Sponsor

3. Body mass index (BMI) between 17 and 35 kg/m2 at screening

4. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol

5. Available for all planned visits and phone calls, and willing to complete all protocol-defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per study dose)

6. Female participants must provide a negative pregnancy test at each required visit and fulfill one of the following criteria:

7. Male participants must agree not to father a child or donate sperm, as well as to use contraception/barrier (a male condom) or be abstinent from heterosexual intercourse during the study active period (Day 29)

1. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed at baseline

2. Cancer, or received treatment for cancer, within past 3 years (excluding basal cell carcinoma or squamous cell carcinoma)

3. Presence of immunosuppression or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus 1 and 2

4. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine Norwalk GI.1 (VXA-G1.1-NN) Protocol No. VXA-NVV-106 ________________________________________________________________________________ _________________________________________________________________________________ Version 1.2 Confidential Page 11 of 42 Date: 04 Jan 2022 Such conditions may include but are not limited to:

5. History of any form of angioedema

6. History of serious reactions to any vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain

7. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic

8. Any condition that resulted in the absence or removal of the spleen

9. Acute disease within 72 hours prior to vaccination defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical exam); assessment may be repeated during screening period

10. Presence of a fever ≥ 38oC measured orally at baseline; assessment may be repeated during screening period

11. Laboratory values outside the range of normal for platelet counts and the following coagulation tests: PT/INR, aPTT and fibrinogen

12. Any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:

13. Any significant hospitalization within the last year which in the opinion of Norwalk GI.1 (VXA-G1.1-NN) Protocol No. VXA-NVV-106

14. Any other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a participant taking in the study, would render the participant unable to comply with the protocol or would interfere with the evaluation of the study endpoints

15. Positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) tests at screening visit

16. Positive urine drug screen for drugs of abuse at screening

17. Positive breath or urine alcohol test at screening and baseline

18. Receipt of a licensed vaccine within 14 days prior to baseline vaccination or planned administration during the study active period

19. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days prior to study drug administration or planned use during the active study period

20. Use of medications known to affect the immune function (e.g., systemic corticosteroids and others) within 2 weeks before study vaccination or planned use during the active period

21. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study vaccination or planned use during the active study period

22. Administration of any investigational vaccine, drug or device within 8 weeks preceding study vaccination (Day 1), or planned use within the duration of the study

23. Donation or use of blood or blood products within 30 days prior to study vaccination or planned donation during the active study period

24. History of drug, alcohol or chemical abuse within 1 year of screening

25. History of hypersensitivity or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin